Hydroxychloroquine overcomes cabergoline resistance in a patient with Lactotroph Pituitary neuroendocrine tumor: a case report
ObjectiveA 22-year-old man complaining erectile dysfunction underwent transsphenoidal surgery for a 2.7 cm sellar mass with total resection and was confirmed at pathology to have a lactotroph pituitary neuroendocrine tumor (PiNET). Postoperatively, the patient’s PRL remained at high level and theref...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.955100/full |
| _version_ | 1828523355329789952 |
|---|---|
| author | Shaojian Lin Changxi Han Xiaohui Lou Zhe Bao Wu |
| author_facet | Shaojian Lin Changxi Han Xiaohui Lou Zhe Bao Wu |
| author_sort | Shaojian Lin |
| collection | DOAJ |
| description | ObjectiveA 22-year-old man complaining erectile dysfunction underwent transsphenoidal surgery for a 2.7 cm sellar mass with total resection and was confirmed at pathology to have a lactotroph pituitary neuroendocrine tumor (PiNET). Postoperatively, the patient’s PRL remained at high level and therefore accepted high-dose dopamine receptor agonist (DA) therapy. After over 3 months of bromocriptine (BRC) (15mg/day) and over 3 years of cabergoline (CAB) (3mg/week) therapy, the patient’s prolactin (PRL) never achieved long-term normalization. He was diagnosed with DA-resistant lactotroph PitNET.MethodIn this study, the patient was given hydroxychloroquine (HCQ) (200 mg/d) and CAB (3 mg/w) in combination for four months. His PRL level was tested by blood test every month.ResultsTaking the combination therapy of HCQ and CAB, the patient’s uncontrolled PRL level was normalized within one month and was maintained at the normal level thereafter. Pituitary magnetic resonance imaging (MRI) images with enhancement showed no recurrence. The patient also regained normal sexual function.DiscussionThis is the first report on the combination of HCQ with CAB for the effective treatment of DA-resistant lactotroph pituitary neuroendocrine tumor in a patient, which might provide a novel treatment strategy for clinical management. |
| first_indexed | 2024-12-11T20:26:08Z |
| format | Article |
| id | doaj.art-1133b3cfdca047c48d2d9b9c734c3187 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-12-11T20:26:08Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-1133b3cfdca047c48d2d9b9c734c31872022-12-22T00:51:57ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922022-08-011310.3389/fendo.2022.955100955100Hydroxychloroquine overcomes cabergoline resistance in a patient with Lactotroph Pituitary neuroendocrine tumor: a case reportShaojian Lin0Changxi Han1Xiaohui Lou2Zhe Bao Wu3Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Neurosurgery, Ruian People’s Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Ruian, ChinaDepartment of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaObjectiveA 22-year-old man complaining erectile dysfunction underwent transsphenoidal surgery for a 2.7 cm sellar mass with total resection and was confirmed at pathology to have a lactotroph pituitary neuroendocrine tumor (PiNET). Postoperatively, the patient’s PRL remained at high level and therefore accepted high-dose dopamine receptor agonist (DA) therapy. After over 3 months of bromocriptine (BRC) (15mg/day) and over 3 years of cabergoline (CAB) (3mg/week) therapy, the patient’s prolactin (PRL) never achieved long-term normalization. He was diagnosed with DA-resistant lactotroph PitNET.MethodIn this study, the patient was given hydroxychloroquine (HCQ) (200 mg/d) and CAB (3 mg/w) in combination for four months. His PRL level was tested by blood test every month.ResultsTaking the combination therapy of HCQ and CAB, the patient’s uncontrolled PRL level was normalized within one month and was maintained at the normal level thereafter. Pituitary magnetic resonance imaging (MRI) images with enhancement showed no recurrence. The patient also regained normal sexual function.DiscussionThis is the first report on the combination of HCQ with CAB for the effective treatment of DA-resistant lactotroph pituitary neuroendocrine tumor in a patient, which might provide a novel treatment strategy for clinical management.https://www.frontiersin.org/articles/10.3389/fendo.2022.955100/fullcase reportcabergolinehydroxychloroquinenovel therapyresistant lactotroph pituitary neuroendocrine tumors |
| spellingShingle | Shaojian Lin Changxi Han Xiaohui Lou Zhe Bao Wu Hydroxychloroquine overcomes cabergoline resistance in a patient with Lactotroph Pituitary neuroendocrine tumor: a case report Frontiers in Endocrinology case report cabergoline hydroxychloroquine novel therapy resistant lactotroph pituitary neuroendocrine tumors |
| title | Hydroxychloroquine overcomes cabergoline resistance in a patient with Lactotroph Pituitary neuroendocrine tumor: a case report |
| title_full | Hydroxychloroquine overcomes cabergoline resistance in a patient with Lactotroph Pituitary neuroendocrine tumor: a case report |
| title_fullStr | Hydroxychloroquine overcomes cabergoline resistance in a patient with Lactotroph Pituitary neuroendocrine tumor: a case report |
| title_full_unstemmed | Hydroxychloroquine overcomes cabergoline resistance in a patient with Lactotroph Pituitary neuroendocrine tumor: a case report |
| title_short | Hydroxychloroquine overcomes cabergoline resistance in a patient with Lactotroph Pituitary neuroendocrine tumor: a case report |
| title_sort | hydroxychloroquine overcomes cabergoline resistance in a patient with lactotroph pituitary neuroendocrine tumor a case report |
| topic | case report cabergoline hydroxychloroquine novel therapy resistant lactotroph pituitary neuroendocrine tumors |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2022.955100/full |
| work_keys_str_mv | AT shaojianlin hydroxychloroquineovercomescabergolineresistanceinapatientwithlactotrophpituitaryneuroendocrinetumoracasereport AT changxihan hydroxychloroquineovercomescabergolineresistanceinapatientwithlactotrophpituitaryneuroendocrinetumoracasereport AT xiaohuilou hydroxychloroquineovercomescabergolineresistanceinapatientwithlactotrophpituitaryneuroendocrinetumoracasereport AT zhebaowu hydroxychloroquineovercomescabergolineresistanceinapatientwithlactotrophpituitaryneuroendocrinetumoracasereport |